Intraoral electrostimulator for xerostomia relief: A long-term, multicenter, open-label, uncontrolled, clinical trial

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Volumn 113, Issue 6, 2012, Pages 773-781

  Alajbeg, Ivan ^a   Falcão, Denise P ^b   Tran, Simon D ^c   Martín Granizo, Rafael ^d   Lafaurie, Gloria I ^e   Matranga, Domenica ^f   Pejda, Slavica ^a   Vuletić, Lea ^a   Mantilla, Rubén ^g   Leal, Soraya C ^b   Bezerra, Ana C Barreto ^b   Ménard, Henri A ^h   Kimoto, Suguru ^c,i   Pan, Shaoxia ^c,j   Maniegas, Lourdes ^d   Krushinski, Cheryl A ^k   Melilli, Dario ^l   Campisi, Giuseppina ^l   Paderni, Carlo ^l   Mendoza, Gloria R Bautista ^e   Yepes, Juan F ^m   Lindh, Liselott ⁿ   Koray, Meltem ^o   Mumcu, Gonca ^p   Elad, Sharon ^q,r   Zeevi, Itai ^s   Barrios, Beatriz C Aldape ^t   Sánchez, Rodrigo M López ^t   Lassauzay, Claire ^c,u   Fromentin, Olivier ^c,v   Beiski, Ben Z ^z   Strietzel, Frank P ^w   Konttinen, Yrjö T ^x,y   Wolff, Andy ^z   Zunt, Susan L ^k   more..

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c MCGILL UNIVERSITY   (Canada)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e UNIVERSIDAD EL BOSQUE   (Colombia)

^f UNIVERSITY OF PALERMO   (Italy)

^g Clínica De Artritis Y Rehabilitacioacute n   (Colombia)

^h MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

ⁱ NIHON UNIVERSITY   (Japan)

^j PEKING UNIVERSITY SCHOOL AND HOSPITAL OF STOMATOLOGY   (China)

^k INDIANA UNIVERSITY SCHOOL OF DENTISTRY   (United States)

^l Sezione di Patologia Vegetale   (Italy)

^m UNIVERSITY OF KENTUCKY   (United States)

ⁿ MALMÖ UNIVERSITY   (Sweden)

^o ISTANBUL UNIVERSITY   (Turkey)

^p MARMARA UNIVERSITY   (Turkey)

^q HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^r UNIVERSITY OF ROCHESTER   (United States)

^s HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^t UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^u UNIVERSITÉ CLERMONT AUVERGNE   (France)

^v UNIVERSITÉ PARIS DESCARTES   (France)

^w CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^x HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^y COXA Hospital for Joint Replacement ^*  (Finland)

^z NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862565734     PISSN: 22124403     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oooo.2012.01.012     Document Type: Article

References (50)

1. Sreebny LM, Valdini A. Xerostomia. A neglected symptom. Arch Intern Med 1987;147:1333-7.
2. Billings RJ, Proskin HM, Moss ME. Xerostomia and associated factors in a community-dwelling adult population. Community Dent Oral Epidemiol 1996;24:312-6. (Pubitemid 126489355)
3. Nederfors T, Isaksson R, Mörnstad H, Dahlöf C. Prevalence of perceived symptoms of dry mouth in an adult Swedish population- relation to age, sex and pharmacotherapy. Community Dent Oral Epidemiol 1997;25:211-6. (Pubitemid 127534004)
4. Tabak LA, Levine MJ, Mandel ID, Ellison SA. Role of salivary mucins in the protection of the oral cavity. J Oral Pathol 1982; 11:1-17. (Pubitemid 12182153)
5. Fox PC, Atkinson JC, Macynski AA, Wolff A, Kung DS, Valdez IH, et al. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med 1991;151:1149-52.
6. Thelin WR, Brennan MT, Lockhart PB, Singh ML, Fox PC, Papas AS, Boucher RC. The oral mucosa as a therapeutic target for xerostomia. Oral Dis 2008;14:683-9.
7. Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 2010; 18:1061-79.
8. Strietzel FP, Martín-Granizo R, Fedele S, Lo Russo L, Mignogna M, Reichart PA, Wolff A. Electrostimulating device in the management of xerostomia. Oral Dis 2007;13:206-13.
9. Strietzel FP, Lafaurie GI, Mendoza GR, Alajbeg I, Pejda S, Vuletić L, et al. Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthritis Rheum 2011;63:180-90.
10. Thomson WM, Chalmers JM, Spencer AJ, Williams SM. The xerostomia inventory: a multi-item approach to measuring dry mouth. Community Dent Health 1999;16:12-7.
11. Pai S, Ghezzi EM, Ship JA. Development of a visual analogue scale questionnaire for subjective assessment of salivary dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:311-6. (Pubitemid 33608850)
12. Vissink A, Wolff A, Veerman ECI. Saliva collectors. In: Wong DT, editor. Salivary diagnostics. Ames (OH): Wiley-Blackwell; 2008. p. 37-59.
13. Fox PC, Cummins MJ, Cummins JM. Use of orally administered anhydrous crystalline maltose for relief of dry mouth. J Altern Complement Med 2001;7:33-43. (Pubitemid 32179869)
14. Pocock SJ. Clinical trials-a practical approach. Chichester (UK): John Wiley and Sons; 1993.
15. Burnham KP, Anderson DR. Model selection and inference: a practical information-theoretical approach. 2nd ed. New York: Springer-Verlag; 1998.
16. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Contr 1974;19:716-23.
17. Miller RG. Simultaneous statistical inference. 2nd ed. New York: Springer Verlag; 1981.
18. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS system for mixed models. Cary (NC): SAS Institute; 1996.
19. Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modeling using Stata. College Station (TX): Stata; 2005.
20. Chambers MS, Mellberg JR, Keene HJ, Bouwsma OJ, Garden AS, Sipos T, Fleming TJ. Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: phase I study. Oral Oncol 2006;42:946-53. (Pubitemid 44462753)
21. Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 2010;18:1039-60.
22. Moutsopoulos HM. Sjögren's syndrome. In: Schumacher HRJ, Klippel JH, Koopman WJ, editors. Primer of the rheumatic diseases. Atlanta (GA): Arthritis Foundation; 1993. p. 131-5.
23. Jellema AP, Slotman BJ, Doornaert P, Leemans CR, Langendijk JA. Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:751-60. (Pubitemid 47418408)
24. Pijpe J, Kalk WW, Bootsma H, Spijkervet FK, Kallenberg CG, Vissink A. Progression of salivary gland dysfunction in patients with Sjögren's syndrome. Ann Rheum Dis 2007;66:107-12. (Pubitemid 46044868)
25. Vissink A, Mitchell JB, Baum BJ, Limesand KH, Jensen SB, Fox PC, et al. Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers. Int J Radiat Oncol Biol Phys 2010;78:983-91.
26. Brennan MT, Shariff G, Lockhart PB, Fox PC. Treatment of xerostomia: a systematic review of therapeutic trials. Dent Clin North Am 2002;46:847-56.
27. von Bultzingslowen I, Sollecito TP, Fox PC, Daniels T, Jonsson R, Lockhart PB, et al. Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103 (Suppl):e1-15.
28. Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjogren syndrome: a systematic review. JAMA 2010;304:452-60.
29. Kallenberg CGM, Vissink A, Kroese FGM, Abdulahad WH, Bootsma H. What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis? Arthritis Res Ther 2011;13:205.
30. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003;49:585-93. (Pubitemid 36988314)
31. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740-50. (Pubitemid 41369102)
32. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome. Arthritis Rheum 2010;62:960-8.
33. Kanter JW, Kohlenberg RJ, Loftus EF. Demand characteristics, treatment rationales, and cognitive therapy for depression. Prev Treat 2002;5:article 41.
34. Segal B, Bowman SJ, Fox PC, Vivino FB, Murukutla N, Brodscholl J, et al. Primary Sjögren's syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes 2009;7:46.
35. Meijer JM, Meiners PM, Huddleston Slater JJR, Spijkervet FKL, Kallenberg CGM, Vissink A, Bootsma H. Health-related quality of life, employment and disability in patients with Sjögren's syndrome. Rheumatology 2009;48:1077-82.
36. Ng W-F, Bowman SJ. Primary Sjögren's syndrome: too dry and too tired. Rheumatology 2010;49:844-53.
37. Talal N, Quinn JH, Daniels TE. The clinical effects of electrostimulation on salivary function of Sjogren's syndrome patients. A placebo controlled study. Rheumatol Int 1992;12:43-5.
38. Wong RK, Jones GW, Sagar SM, Babjak AF, Whelan T. A phase I-II study in the use of acupuncture-like transcutaneous nerve stimulation in the treatment of radiation-induced xerostomia in head-and-neck cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:472-80. (Pubitemid 37040944)
39. Hargitai IA, Sherman RG, Strother JM. The effects of electrostimulation on parotid saliva flow: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:316-20. (Pubitemid 40260650)
40. Katz B, Nerve, muscle, and synapse. 5th ed. New York: McGraw-Hill; 1966.
41. Fall M, Lindström S. Functional electrical stimulation: physiological basis and clinical principles. Int Urogynecol J 1994;5: 296-304. (Pubitemid 24310416)
42. Kiesselbach JE, Chamberlain JG. Clinical and anatomic observations on the relationship of the lingual nerve to the mandibular third molar region. J Oral Maxillofac Surg 1984;42:565-7. (Pubitemid 14067952)
43. Grant R, Ferguson MM, Strang R, Turner JW, Bone I. Evoked taste thresholds in a normal population and the application of electrogustometry to trigeminal nerve disease. J Neurol Neurosurg Psychiatry 1987;50:12-21. (Pubitemid 17218351)
44. Steller M, Chou L, Daniels TE. Electrical stimulation of salivary flow in patients with Sjogren's syndrome. J Dent Res 1988;67: 1334-7.
45. Eliav E, Kamran B, Schaham R, Czerninski R, Gracely RH, Benoliel R. Evidence of chorda tympani dysfunction in patients with burning mouth syndrome. J Am Dent Assoc 2007; 138:628-33.
46. Proctor GB, Carpenter GH. Regulation of salivary gland function by autonomic nerves. Auton Neurosc Basic Clin 2007;133:3-18. (Pubitemid 46483257)
47. Månsson B, Nilsson BO, Ekström J. Effects of repeated infusions of substance P and vasoactive intestinal peptide on the weights of salivary glands subjected to atrophying influences in rats. Br J Pharmacol 1990;101:853-8.
48. Ekström J, Reinhold AC. Influence of parasympathetic nonadrenergic, noncholinergic mechanisms on [3H]thymidine uptake in rat parotid salivary glands in response to mastication following upon a liquid regimen. Arch Oral Biol 2001;46:1151-5. (Pubitemid 33086345)
49. Calafat M, Larocca L, Roca V, Hauk V, Pregi N, Nesse A, Pérez Leirós C. Vasoactive intestinal peptide inhibits TNF-alpha- induced apoptotic events in acinar cells from nonobese diabetic mice submandibular glands. Arthritis Res Ther 2009; 11:R53.
50. Konttinen YT, Vivó PA, Porola P, Koskenpato K, Lorés RM, Pöllänen R, et al. Neurobiology and hormonal control of lacrimal and salivary gland function. In: Fox R, Fox C, editors. Sjögren's syndrome: a multidisciplinary guide to pathogenesis and treatment. New York: Humana; 2011.